FGFR2 Mutation

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Cholangiocarcinoma5
FGFR2 Mutation	Erdafitinib	Predictive	C	Supports Sensitivity Response	3	submitted	EID10375 Phase I dose-escalation cohort (NCT01703481) of patients with advanced solid tumors in which antineoplastic therapy was no longer effective using pan-FGFR inhibitor erdafitinib (JNJ-42756493). 1 chola… (full text at CIViC) PMID 31088831 · Bahleda et al., 2019 · Open in CIViC	civic
FGFR2 Mutation	Erdafitinib	Predictive	C	Does Not Support Sensitivity Response	3	submitted	EID10398 Phase I dose-escalation cohort (NCT01703481) of patients with advanced solid tumors in which antineoplastic therapy was no longer effective using pan-FGFR inhibitor JNJ-42756493. 2 cholangiocarcinoma … (full text at CIViC) PMID 31088831 · Bahleda et al., 2019 · Open in CIViC	civic

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Cholangiocarcinoma5

FGFR2 Mutation

Erdafitinib

Predictive

Supports Sensitivity Response

submitted

EID10375

Phase I dose-escalation cohort (NCT01703481) of patients with advanced solid tumors in which antineoplastic therapy was no longer effective using pan-FGFR inhibitor erdafitinib (JNJ-42756493). 1 chola… (full text at CIViC)

PMID 31088831 · Bahleda et al., 2019 · Open in CIViC

civic

FGFR2 Mutation

Erdafitinib

Predictive

Does Not Support Sensitivity Response

submitted

EID10398

Phase I dose-escalation cohort (NCT01703481) of patients with advanced solid tumors in which antineoplastic therapy was no longer effective using pan-FGFR inhibitor JNJ-42756493. 2 cholangiocarcinoma … (full text at CIViC)

PMID 31088831 · Bahleda et al., 2019 · Open in CIViC

civic

Malignant Endometrial Neoplasm3
FGFR2 Mutation	(prognostic)	Prognostic	B	Supports Poor Outcome	2	submitted	EID6444 patients with FGFR2 mutations had a much higher incidence of progression (32/125, 26%) whereas among those with wild type where only (120/848,14%) displayed incidences of progression. The mutated FGFR… (full text at CIViC) PMID 28314589 · Jeske et al., 2017 · Open in CIViC	civic
FGFR2 Mutation	Dovitinib + FulvestrantCombination	Predictive	B	Supports Sensitivity Response	3	submitted	EID6457 Treatment of cell lines harboring FGFR2 mutations with dovitinib 0.5 mmol/L for 72 hours resulted in a significant decrease in cell viability of AN3CA (37.80%) and MFE-296 (53.14%). Conversely, in cel… (full text at CIViC) PMID 24448819 · Eritja et al., 2014 · Open in CIViC	civic
FGFR2 Mutation	Ponatinib	Predictive	D	Supports Sensitivity Response	3	accepted	EID1236 Preclinical study in endometrial cancer cell lines (MFE-296, AN3CA, MFE-280 and Ishikawa). In cell proliferation assays, the three FGFR2 mutant cell lines were more sensitive to the pan-FGFR inhibitor… (full text at CIViC) PMID 26574622 · Kim et al., 2016 · Open in CIViC	civic

Malignant Endometrial Neoplasm3

FGFR2 Mutation

(prognostic)

Prognostic

Supports Poor Outcome

submitted

EID6444

patients with FGFR2 mutations had a much higher incidence of progression (32/125, 26%) whereas among those with wild type where only (120/848,14%) displayed incidences of progression. The mutated FGFR… (full text at CIViC)

PMID 28314589 · Jeske et al., 2017 · Open in CIViC

civic

FGFR2 Mutation

Dovitinib + FulvestrantCombination

Predictive

Supports Sensitivity Response

submitted

EID6457

Treatment of cell lines harboring FGFR2 mutations with dovitinib 0.5 mmol/L for 72 hours resulted in a significant decrease in cell viability of AN3CA (37.80%) and MFE-296 (53.14%). Conversely, in cel… (full text at CIViC)

PMID 24448819 · Eritja et al., 2014 · Open in CIViC

civic

FGFR2 Mutation

Ponatinib

Predictive

Supports Sensitivity Response

accepted

EID1236

Preclinical study in endometrial cancer cell lines (MFE-296, AN3CA, MFE-280 and Ishikawa). In cell proliferation assays, the three FGFR2 mutant cell lines were more sensitive to the pan-FGFR inhibitor… (full text at CIViC)

PMID 26574622 · Kim et al., 2016 · Open in CIViC

civic

Malignant Neoplasm1
FGFR1 Amplification OR FGFR2 Mutation OR v::FGFR1 Fusion OR FGFR2 Amplification OR FGFR3 Mutation OR FGFR3::v Fusion	Fexagratinib	Predictive	B	Does Not Support Sensitivity Response	3	submitted	EID11675 In this NCI-MATCH trial subprotocol W, 48 patients harbouring FGFR1 or FGFR2 amplification (n = 20), FGFR2 or FGFR3 single-nucleotide variants (n=19), or FGFR1 or FGFR3 fusions (n=9) were treated with… (full text at CIViC) PMID 32463741 · Chae et al., 2020 · Open in CIViC	civic

Malignant Neoplasm1

FGFR1 Amplification OR FGFR2 Mutation OR v::FGFR1 Fusion OR FGFR2 Amplification OR FGFR3 Mutation OR FGFR3::v Fusion

Fexagratinib

Predictive

Does Not Support Sensitivity Response

submitted

EID11675

In this NCI-MATCH trial subprotocol W, 48 patients harbouring FGFR1 or FGFR2 amplification (n = 20), FGFR2 or FGFR3 single-nucleotide variants (n=19), or FGFR1 or FGFR3 fusions (n=9) were treated with… (full text at CIViC)

PMID 32463741 · Chae et al., 2020 · Open in CIViC

civic

Transitional Cell Carcinoma1
FGFR2 Mutation OR FGFR2::v Fusion OR FGFR2::? Fusion	Erdafitinib	Predictive	A	Supports Sensitivity Response	4	accepted	EID7261 Patients with metastatic or unresectable urothelial carcinoma havoring FGFR2 fusion, FGFR3 fusion or FGFR3 mutation were treated with pan-FGFR inhibitor, erdafitinib, in Phase 2 trial. 96 patients wer… (full text at CIViC) Open in CIViC	civic

Transitional Cell Carcinoma1

FGFR2 Mutation OR FGFR2::v Fusion OR FGFR2::? Fusion

Erdafitinib

Predictive

Supports Sensitivity Response

accepted

EID7261

Patients with metastatic or unresectable urothelial carcinoma havoring FGFR2 fusion, FGFR3 fusion or FGFR3 mutation were treated with pan-FGFR inhibitor, erdafitinib, in Phase 2 trial. 96 patients wer… (full text at CIViC)

Open in CIViC

civic

Evidence by cancer (10 items)

Clinical significance (0)